Stem Cell Therapy for Ischaemic Disease

When the human heart muscle receives insufficient quantity of blood, it leads to dry up of vessels. This condition of person suffering subjected as Ischaemic disease. This disease gradually decreases muscle of the heart from its ideal functioning, resulting to a heart attack. Scientifically the condition called as myocardial infarction.

Ischaemic heart disease treatable by stem cell therapy

Stem cell researchers have found a mechanism to treat the damaged heart muscles by cardiomyocytes, known fibers cell. Even due to the condition of aging will lead the muscles contraction failure by inhibiting the hearts involuntary action. By the myocardial replacement therapy, new cardiomyocytes cells generation takes place and improve the function of the heart. As per research, even the damaged heart can treated and resorted to its normal function by steam cell therapy.

It is new therapeutic tool. To treat ischemic heart disease mesenchymal/ hematopoietic stem cells are used. Researchers extract these cells from adipose tissues and bone marrow. However, the performances of regeneration and repair of these cells strongly affected by the factors like hypertension, diabetes mellitus and obesity. Most heart related adult deaths in United States caused by ischemic heart disease.

When we consider hematopoietic stem cells, scientist found that they settled at peritoneal cavities. By dialysis, they collect and use these cells for treatment of heart problems.

Properties of hematopoietic preferred for stem cell therapy:

  • Good self-renewability, stability and resilience
  • Distinguishable into every blood cell types
  • Can be obtained from bone marrow, umbilical cord blood and mobilize peripheral blood
  • Ability to develop all cells that belongs to human hematopoietic system

Vitro micronucleus assay is used to known genotoxicity and sensitivity during induction of micronucleated reticulocytes.  Because when these cells damaged, they lead to leukaemia.

Medical stem cell therapy concludes that intramyocardial bmc injection enhances the left ventricular dysfunction and decline in left ventricular capacity.